 This study is planning to evaluate the safety and clinical efficacy of medium-chain fatty acid capsules food-grade CNT-02 in subjects with primary triglyceride deposit cardiomyovasculopathy TGCV and neutral lipid storage disease with myopathy NLSD-M associated with adipose triglyceride lipase ATGL genetic defects. 